A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes
2022 · Nature Cancer · 124 citations
https://doi.org/10.1038/s43018-022-00439-1
J
Joshua J. Gruber
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
109
Papers
3.3K
Citations
24
h-index
29
i10-index
Joshua J. Gruber is an academic researcher from University of California, Davis. The author has contributed to research in topics: Cancer, Hypoxia, and Metabolism & Epigenetics and DNA Methylation & Neuroblastoma Research and Treatments. The author has an h-index of 24, co-authored 93 publications.
ORCID: 0000-0002-8642-6074Papers by this author
worksAI is a viable alternative to high throughput screening: a 318-target study
2024 · Scientific Reports · 114 citations
https://doi.org/10.1038/s41598-024-54655-z
Short-chain fatty acid metabolites propionate and butyrate are unique epigenetic regulatory elements linking diet, metabolism and gene expression
2025 · Nature Metabolism · 88 citations
https://doi.org/10.1038/s42255-024-01191-9
Acetate supplementation restores chromatin accessibility and promotes tumor cell differentiation under hypoxia
2020 · Cell Death and Disease · 64 citations
https://doi.org/10.1038/s41419-020-2303-9
Loss of the Birt–Hogg–Dubé tumor suppressor results in apoptotic resistance due to aberrant TGFβ-mediated transcription
2011 · Oncogene · 62 citations
https://doi.org/10.1038/onc.2010.628
Human genome meeting 2016
2016 · Human Genomics · 41 citations
https://doi.org/10.1186/s40246-016-0063-5
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat